kwic
studies
studies
right
off
ON
417
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for studies out of >500 occurrences
532339 occurrences (No.23 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to studies]
532339 occurrences (No.23 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 417) The outcome of these studies will be reviewed. |
| PMID:23968273 DOI:10.3109/14767058.2013.796165 |
| 2015 The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians |
| * Intraventricular haemorrhage in preterm infants--can we improve outcome by addressing coagulation? |
| - During the last few decades, the survival of preterm infants has increased dramatically. Nevertheless, with the increasing number of very young and extremely low birth weight infants, morbidity is still a major problem. Intraventricular Haemorrhage (IVH) is a major complication of preterm birth, and large haemorrhages or haemorrhages associated with parenchymal brain lesions may yield a high rate of future disability. IVH is a complex, multi-factorial disorder. Prematurity and low birth weight remain as its most important risk factors, affecting vulnerability of the germinal matrix as well as the coagulation system. Approximately 80% of IVHs occur by 72 h after birth, but a considerable proportion of IVH is already visible on the first cranial ultrasound scan within a few hours of birth. The hypothesis that a severe coagulation deficiency in the premature newborn could be a major contributing factor to IVH has been suggested, and small open label interventional studies targeting the premature coagulation system have been conducted with ethamsylate, vitamin K, fresh frozen plasma, recombinant activated factor VII and prothrombin complex concentrate. The outcome of these studies will be reviewed. |
[
right
kwic]
(1)61  have |
(14)8 with |
(27)3 demonstrate |
(40)2 including |
| (2)47 *null* | (15)7 should |
(28)3 for |
(41)2 indicated |
| (3)32 of |
(16)6 is |
(29)3 however, |
(42)2 investigating |
| (4)26 are |
(17)6 we |
(30)3 performed |
(43)2 involving |
| (5)26 on |
(18)5 suggest |
(31)3 reported |
(44)2 it |
| (6)19 in |
(19)5 the |
(32)3 since |
(45)2 or |
| (7)17 were |
(20)4 as |
(33)3 which |
(46)2 provide |
| (8)16 and |
(21)4 demonstrated |
(34)2 about |
(47)2 published |
| (9)15 to |
(22)4 evaluating |
(35)2 also |
(48)2 regarding |
| (10)10 showed |
(23)4 from |
(36)2 can |
(49)2 targeting |
| (11)8 revealed |
(24)4 indicate |
(37)2 concerning |
(50)2 tested |
| (12)8 that |
(25)4 show |
(38)2 demonstrating |
(51)2 used |
| (13)8 using |
(26)3 based |
(39)2 has |
(52)2 was |
add keyword
--- WordNet output for studies ---